MX2018015463A - Co-cristales de benzoato de litio y sus usos. - Google Patents
Co-cristales de benzoato de litio y sus usos.Info
- Publication number
- MX2018015463A MX2018015463A MX2018015463A MX2018015463A MX2018015463A MX 2018015463 A MX2018015463 A MX 2018015463A MX 2018015463 A MX2018015463 A MX 2018015463A MX 2018015463 A MX2018015463 A MX 2018015463A MX 2018015463 A MX2018015463 A MX 2018015463A
- Authority
- MX
- Mexico
- Prior art keywords
- crystals
- disorders
- lithium benzoate
- lithium
- benzoatecompound
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 3
- 229940031993 lithium benzoate Drugs 0.000 title 1
- LDJNSLOKTFFLSL-UHFFFAOYSA-M lithium;benzoate Chemical compound [Li+].[O-]C(=O)C1=CC=CC=C1 LDJNSLOKTFFLSL-UHFFFAOYSA-M 0.000 title 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052744 lithium Inorganic materials 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
- C07C57/10—Sorbic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
- C07C57/44—Cinnamic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349582P | 2016-06-13 | 2016-06-13 | |
| PCT/CN2017/088044 WO2017215592A1 (en) | 2016-06-13 | 2017-06-13 | Co-crystals of lithium benzoate and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018015463A true MX2018015463A (es) | 2019-05-27 |
Family
ID=60663075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015463A MX2018015463A (es) | 2016-06-13 | 2017-06-13 | Co-cristales de benzoato de litio y sus usos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10815184B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3468946A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6958923B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102488927B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109563024B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3027300C (cg-RX-API-DMAC7.html) |
| IL (1) | IL263486B (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018015463A (cg-RX-API-DMAC7.html) |
| RU (2) | RU2022101542A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI736635B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017215592A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI671287B (zh) * | 2016-06-13 | 2019-09-11 | 心悅生醫股份有限公司 | 苯甲酸鈉之共晶及其用途 |
| US11376277B2 (en) | 2020-06-01 | 2022-07-05 | Celagenex Research (India) Pvt. Ltd. | Synergistic medicinal compositions for treating dysfunctional D-serine signaling |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3498989A (en) | 1969-04-16 | 1970-03-03 | American Home Prod | Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof |
| US3870715A (en) | 1972-03-09 | 1975-03-11 | Nikolaus R Hansl | Substituted amino ethyl meta benzoic acid esters |
| US4041174A (en) | 1974-08-16 | 1977-08-09 | Rom-Amer Pharmaceuticals, Ltd. | Method of treating depression |
| US5204356A (en) | 1985-07-24 | 1993-04-20 | Glaxo Group Limited | Treatment of anxiety |
| US6150354A (en) | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| GB8819494D0 (en) | 1988-08-16 | 1988-09-21 | Ucb Sa | Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments |
| US6746678B1 (en) | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| CA2104594C (en) * | 1991-02-22 | 2004-05-11 | Howard K. Shapiro | Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| FR2700117B1 (fr) | 1993-01-07 | 1995-02-03 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. |
| DE4340273A1 (de) | 1993-11-26 | 1995-06-01 | Karla Dr Lehmann | Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung |
| US5453425A (en) | 1994-07-11 | 1995-09-26 | Janssen Pharmaceutica N.V. | Risperidone oral formulation |
| AU4517201A (en) | 1999-12-08 | 2001-06-18 | Vanderbilt University | Modulation of in vivo glutamine and glycine levels in the treatment of autism |
| WO2002014286A1 (en) | 2000-08-14 | 2002-02-21 | Teva Pharmaceutical Industries Ltd. | Preparation of risperidone |
| EA006654B1 (ru) | 2001-01-16 | 2006-02-24 | Женсет С. А. | Лечение нарушений центральной нервной системы с использованием антагонистов оксидазы d-аминокислот и d-аспартатоксидазы |
| US20030185754A1 (en) | 2001-01-16 | 2003-10-02 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US20070053976A1 (en) | 2002-05-17 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Novel combination of drugs as antidepressant |
| US7053122B2 (en) | 2002-08-09 | 2006-05-30 | Pfizer Inc | Therapeutic use of aryl amino acid derivatives |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| WO2004037234A2 (en) | 2002-10-24 | 2004-05-06 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| WO2004065348A1 (en) | 2003-01-23 | 2004-08-05 | Pfizer Products Inc. | Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof |
| JP2006526635A (ja) | 2003-06-02 | 2006-11-24 | サマリタン,ファーマスーティカルス,インク. | 血清中コルチゾール量を調節する方法および組成物 |
| BRPI0417910A (pt) | 2003-12-29 | 2007-04-10 | Sepracor Inc | composto ou um sal ou salvato farmaceuticamente aceitáveis do mesmo, e, uso de um composto |
| EP1709053B1 (en) | 2004-01-27 | 2011-04-06 | Synthon B.V. | Stable salts of olanzapine |
| US20050267176A1 (en) | 2004-02-18 | 2005-12-01 | Sepracor Inc. | Dopamine-agonist combination therapy for improving sleep quality |
| CA2565159A1 (en) | 2004-05-06 | 2005-12-15 | Cydex, Inc. | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin |
| WO2006007448A2 (en) | 2004-06-17 | 2006-01-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions and related methods of use |
| WO2006096439A2 (en) | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| CA2505808A1 (en) * | 2005-05-02 | 2006-11-02 | Julie Danielle Globus | Niacin used as oral supplementation for the treatment of psychosis and/or schizophrenia in humans |
| WO2006129160A2 (en) | 2005-06-01 | 2006-12-07 | Aurobindo Pharma Limited | Stable aqueous oral solution of risperidone |
| US20110045065A1 (en) | 2005-07-11 | 2011-02-24 | Ashok Vasantray Vyas | Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof |
| US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
| GB0603181D0 (en) | 2006-02-17 | 2006-03-29 | Merck Sharp & Dohme | Treatment of neurodegenerative and psychiatric diseases |
| US20080045512A1 (en) | 2006-08-09 | 2008-02-21 | Pfizer Inc. | Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane |
| WO2008034087A2 (en) | 2006-09-15 | 2008-03-20 | Xenoport, Inc. | Treating schizophrenia with combinations of levodopa and an antipsychotic agent |
| US8071143B2 (en) | 2008-04-02 | 2011-12-06 | Brandeis University | Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances |
| US20130338199A1 (en) * | 2008-07-11 | 2013-12-19 | Uday Saxena | Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease |
| US8541435B2 (en) * | 2008-07-11 | 2013-09-24 | Uday Saxena | Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of Alzheimer's disease (AD) |
| GB0813709D0 (en) | 2008-07-26 | 2008-09-03 | Univ Dundee | Method and product |
| JP2010106001A (ja) * | 2008-10-31 | 2010-05-13 | Theravalues Corp | Ppar活性化剤 |
| EP3006024B1 (en) | 2009-01-20 | 2019-03-20 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Benzoic acid or salts thereof to enhance the activity of a neuropharmaceutical |
| DK3656765T3 (da) * | 2010-07-23 | 2021-06-14 | Gruenenthal Gmbh | Salte eller co-krystaller af 3-(3-dimethylamin-1-ethyl-2-methyl-propyl)-phenol |
| JP2014508814A (ja) * | 2011-03-24 | 2014-04-10 | ユニバーシティ・オブ・サウス・フロリダ | リチウム組成物 |
| TWI542596B (zh) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體 |
| US9120766B2 (en) * | 2011-10-21 | 2015-09-01 | Amri Ssci, Llc | Methods of making cocrystals |
| ES2910003T3 (es) * | 2013-04-19 | 2022-05-11 | Univ South Florida | Compuestos y composiciones de cocristal iónico de litio de anión orgánico |
| WO2014178040A1 (en) | 2013-04-29 | 2014-11-06 | Mapi Pharma Ltd. | Co-crystals of dapagliflozin |
| ES2788866T3 (es) * | 2013-12-13 | 2020-10-23 | Conaris Res Institute Ag | Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida para su uso en influir beneficiosamente en los niveles de lípidos en sangre mediante la modificación de la microbiota intestinal |
| SG11201507188QA (en) * | 2014-03-24 | 2015-10-29 | Kaohsiung Chang Gung Memorial Hospital | Use of benzoic acid salt in the manufacture of a composition for preventing or treating dementia or mild cognitive impairment |
| CN103992320A (zh) | 2014-05-26 | 2014-08-20 | 南京工业大学 | 一种混悬结晶制备药物共晶的方法 |
| WO2016081365A1 (en) * | 2014-11-19 | 2016-05-26 | Rush University Medical Center | Compositions and methods for treating lysosomal disorders |
| RU2582962C1 (ru) | 2014-12-23 | 2016-04-27 | Ольга Алексеевна Громова | Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты) |
| TWI671287B (zh) | 2016-06-13 | 2019-09-11 | 心悅生醫股份有限公司 | 苯甲酸鈉之共晶及其用途 |
-
2017
- 2017-06-13 KR KR1020217037292A patent/KR102488927B1/ko active Active
- 2017-06-13 CN CN201780047178.3A patent/CN109563024B/zh active Active
- 2017-06-13 JP JP2018564930A patent/JP6958923B2/ja active Active
- 2017-06-13 CA CA3027300A patent/CA3027300C/en active Active
- 2017-06-13 RU RU2022101542A patent/RU2022101542A/ru unknown
- 2017-06-13 EP EP17812703.1A patent/EP3468946A4/en active Pending
- 2017-06-13 RU RU2018146423A patent/RU2765625C2/ru active
- 2017-06-13 MX MX2018015463A patent/MX2018015463A/es unknown
- 2017-06-13 WO PCT/CN2017/088044 patent/WO2017215592A1/en not_active Ceased
- 2017-06-13 US US16/309,370 patent/US10815184B2/en active Active
- 2017-06-13 TW TW106119578A patent/TWI736635B/zh active
- 2017-06-13 KR KR1020197000865A patent/KR102338171B1/ko active Active
-
2018
- 2018-12-04 IL IL263486A patent/IL263486B/en unknown
-
2020
- 2020-09-23 US US17/030,222 patent/US11739046B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210107856A1 (en) | 2021-04-15 |
| JP2019518757A (ja) | 2019-07-04 |
| RU2018146423A (ru) | 2020-07-14 |
| TW201811321A (zh) | 2018-04-01 |
| RU2018146423A3 (cg-RX-API-DMAC7.html) | 2020-10-06 |
| RU2765625C2 (ru) | 2022-02-01 |
| CA3027300C (en) | 2023-08-08 |
| EP3468946A4 (en) | 2020-02-12 |
| RU2022101542A (ru) | 2022-02-03 |
| US20190177261A1 (en) | 2019-06-13 |
| IL263486A (en) | 2019-01-31 |
| JP6958923B2 (ja) | 2021-11-02 |
| KR102488927B1 (ko) | 2023-01-13 |
| KR20190017939A (ko) | 2019-02-20 |
| KR20210142769A (ko) | 2021-11-25 |
| US11739046B2 (en) | 2023-08-29 |
| CN109563024A (zh) | 2019-04-02 |
| IL263486B (en) | 2021-08-31 |
| EP3468946A1 (en) | 2019-04-17 |
| CA3027300A1 (en) | 2017-12-21 |
| TWI736635B (zh) | 2021-08-21 |
| KR102338171B1 (ko) | 2021-12-09 |
| US10815184B2 (en) | 2020-10-27 |
| WO2017215592A1 (en) | 2017-12-21 |
| CN109563024B (zh) | 2023-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| PH12018500140A1 (en) | Colony stimulating factor-1 receptor (csf-1r) inhibitors | |
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| IL246875A0 (en) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for the treatment of Alzheimer's disease | |
| MX2021008281A (es) | Estimuladores de guanilato ciclasa soluble (sgc). | |
| TW201613872A (en) | IRAK4 inhibiting agents | |
| IL252091A0 (en) | 2-amino-5,3-difluoro-6,3-dimethyl-6-phenyl-6,5,4,3-tetrahydropyridines as bace1 inhibitors for the treatment of Alzheimer's disease | |
| MY177031A (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| CL2018000375A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1. | |
| NZ738672A (en) | Therapeutic compounds and compositions for treating social disorders and substance use disorders | |
| TN2017000196A1 (en) | 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139 | |
| MY186271A (en) | Ophthalmic compositions and methods of use therefor | |
| PH12017501028A1 (en) | Treatment of retinal degeneration using progenitor cells | |
| MX388612B (es) | Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos. | |
| PH12016501613B1 (en) | Pyrazines modulators of gpr6 | |
| ZA201606471B (en) | Antimitotic amides for the treatment of cancer and proliferative disorders | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| MX2018015463A (es) | Co-cristales de benzoato de litio y sus usos. | |
| MX2016012246A (es) | Derivados de fenilpiperidincarboxamida como fungicidas. | |
| GEP20207127B (en) | 2-homopiperazine-1-yl-4h-1,3-benzothiazine-4-one derivatives and process for the preparation of 2-(homo)piperazine 1,3-benzothiazine-4-one hydrochlorides | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| PH12016502477A1 (en) | Novel polymorphic form of n-[2-(6-fluoro-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer`s |